Tirzepatide denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Tirzepatide as Non-Formulary — and Why You Can Appeal

A non-formulary denial from UnitedHealthcare means tirzepatide is not included on your specific plan's drug list, or is placed at a tier that is effectively inaccessible due to cost-sharing. Non-formulary denials feel final, but most plans have a formulary exception process that is legally required to consider your medical circumstances — and federal law gives you the right to appeal.

## Why This Denial Is Appealable

Under ACA rules and most state insurance codes, you have the right to request a formulary exception when: (a) all formulary alternatives have been tried and are inadequate or contraindicated, or (b) a formulary alternative is not clinically appropriate for your specific situation. Your prescriber's medical judgment about why tirzepatide is necessary and why on-formulary alternatives are insufficient is the core of this appeal. UHC cannot deny a formulary exception without engaging with that individualized clinical rationale.

## Federal Appeal Framework

• Internal appeal / formulary exception: Request a formulary exception first — this is typically a faster track than a formal internal appeal and uses the same clinical-necessity standard. If the exception is denied, it triggers full internal appeal rights under ERISA §503 or applicable state law.
• External review: Under ACA §2719, formulary exception denials are reviewable by an independent external reviewer after the internal process is exhausted. The external-review window is generally within approximately four months of the final internal denial.
• Expedited review: Available when your health would be seriously jeopardized by delay; typically decided within 72 hours.

## Concrete Appeal Steps

1. Ask UHC for the list of on-formulary alternatives in the same therapeutic category. 2. Review that list with your prescriber and document why each alternative is clinically inadequate or inappropriate for you. 3. Have your prescriber submit a formulary exception request with a medical-necessity letter covering each alternative. 4. If the exception is denied, file the formal internal appeal using the denial letter's instructions. 5. Escalate to external review if the internal appeal fails.

## Documentation to Gather

• Trial and failure records: For each formulary alternative UHC identifies, document prior use (dates, clinical response, adverse effects) or a prescriber-documented clinical reason it is inappropriate.
• Prescriber medical-necessity letter: Addresses why tirzepatide is necessary for this patient and why the on-formulary alternatives are not clinically equivalent or appropriate.
• Diagnosis and clinical records: Chart notes establishing the underlying condition and clinical severity.
• FDA label reference: Confirm tirzepatide's approved indication matches your diagnosis — this supports the medical-necessity argument.

## Criteria-Mapping Structure

For each formulary alternative UHC lists, create a row: the drug name, whether you tried it (with dates and outcomes from the chart), and your prescriber's documented clinical reason it is or would be inadequate. Attach pharmacy records and chart notes for each prior agent. Then map each of UHC's formulary-exception criteria to your evidence in the same two-column format, citing specific chart dates and prescriber letter paragraphs.